

comprising an isolated IL-16 antagonist peptide consisting of the amino acid sequence of SEQ ID NO: 24 and a pharmaceutically acceptable carrier. However, the Examiner contends that the specification does not provide enablement for a pharmaceutical composition comprising any IL-16 antagonist peptide and a pharmaceutically acceptable carrier.

In an effort to favorably advance the prosecution of the present application, Applicants have amended claim 35 and have added claim 43 in accordance with the Examiner's suggestion. Applicants reserve the right to pursue the subject matter relating to pharmaceutical compositions comprising an IL-16 antagonist peptide and a pharmaceutically acceptable carrier, as encompassed by original claim 35, in a continuation application.

In view of the foregoing, the rejection of claim 35 under 35 U.S.C. § 112, first paragraph (enablement) is overcome. Withdrawal of the rejection is therefore respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the instant amendment. The attached page is captioned "Version with Markings to Show Changes Made."

It is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Frank S. DiGiglio  
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516)-742-4343

FSD/XZ:ab

Enclosures: Version with Markings to Show Changes Made

Serial No: 09/368,630

Docket: 12875

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the claims:**

**Please amend claim 35 as follows:**

35. (Twice Amended) A [pharmaceutical] composition comprising the isolated peptide of any of Claims 2-4, 6, 14 or 22 and a pharmaceutically acceptable carrier.

**Please add the following claim:**

**43. A pharmaceutical composition comprising the isolated peptide of SEQ ID NO: 24 and a pharmaceutically acceptable carrier.**